Business Summary

Paradigm Biopharmaceuticals Limited is a late-stage drug development company that is engaged in researching and developing therapeutic products for human use. The Company is focused on developing and commercializing pentosan polysulfate sodium (PPS) for the treatment of pain associated with musculoskeletal disorders driven by injury, inflammation, ageing, degenerative disease, infection, or genetic predisposition. PPS is a semi-synthetic drug manufactured from European beech xylans that are sulfated to produce a negatively charged product that mimics glycosaminoglycans (GAGs). Its multiple actions of PPS are mediated by targeting both NF-kB-dependent and NF-kB-independent pathways. The Company focuses on repurposing PPS for the treatment of Osteoarthritis (OA) and bone marrow lesions (BML), mucopolysaccharidosis (MPS), chronic heart failure (CHF) and alpha-viral arthritis (Ross River Virus and Chikungunya).